DDrare: Database of Drug Development for Rare Diseases

211. 左心低形成症候群
［臨床試験数：20，薬物数：28（DrugBank：9），標的遺伝子数：5，標的パスウェイ数：13］

Searched query = "Hypoplastic left heart syndrome", "HLHS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Allo-hMSCs; Ambrisentan; Autologous (self) mononuclear cells derived from umbilical cord blood; Autologous Human Placental Cord Blood Mononuclear Cells; Autologous Umbilical Cord Blood; Autologous cell-based delivery; Bosentan; C-kit+ cells; Curosurf; Erythropoetin; Longeveron Mesenchymal Stem Cells; METHYLPREDNISOLONE SODIUM SUCCINATE; MPC; Maternal Hyperoxygenation; Maternal hyperoxygenation; Methylprednisolone; Metyyliprednisoloninatriumsuksinaatti; Nitrogen; Normal saline; Oxandrolone; Procedure: Stage II Surgical repair; Rexlemestrocel-L; Sham; Sildenafil; Solu-Medrol; Solu-medrol; Tracleer; Vitamin C

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02398604 (ClinicalTrials.gov)	April 2015	24/12/2014	Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome	Allogeneic Human MEsenchymal Stem Cell (hMSC) Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study.	Hypoplastic Left Heart Syndrome	Drug: Allo-hMSCs;Drug: Placebo	Joshua M Hare	University of Maryland, College Park	Terminated	N/A	30 Days	All	5	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02398604
(ClinicalTrials.gov)

April 2015

24/12/2014

Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome

Allogeneic Human MEsenchymal Stem Cell (hMSC) Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study.

Hypoplastic Left Heart Syndrome

Drug: Allo-hMSCs;Drug: Placebo

Joshua M Hare

University of Maryland, College Park

Terminated

N/A

30 Days

All

Phase 1

United States